title: Biomarkers as end points in clinical trials of severe sepsis: a garden of forking paths.
authors.forename: Jorge I F
authors.initials: JI
authors.lastname: Salluh
authors.forename: Pedro
authors.initials: P
authors.lastname: Póvoa
mesh_terms: D015415:Biomarkers / Q000097:blood; D003422:Critical Care / Q000592:standards / Q000639:trends; D006801:Humans; D007362:Intensive Care Units; D015850:Interleukin-6 / Q000097:blood*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018805:Sepsis / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality*; D013449:Sulfonamides / Q000627:therapeutic use; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D015850:Interleukin-6; D013449:Sulfonamides; C507035:ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate